CSIMarket
 
Avita Medical Inc   (NASDAQ: RCEL)
 
Price: $11.2000 $0.26 2.377%
Day's High: $11.390000343322754 Week Perf: 10.89 %
Day's Low: $ 10.80 30 Day Perf: 135.79 %
Volume (M): 301,598 52 Wk High: $ 11.39
Volume (M$): $ 0 52 Wk Avg: $4.74
Open: $10.99 52 Wk Low: $3.22



 Market Capitalization (Millions $) 344
 Shares Outstanding (Millions) 31
 Employees 226
 Revenues (TTM) (Millions $) 76
 Net Income (TTM) (Millions $) -43
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 1

Business Description


Avita Medical Inc is a global regenerative medicine company that specializes in the development and commercialization of advanced therapeutic solutions for skin regeneration. The company is known for its innovative technology called ReCell, which enables medical professionals to rapidly and efficiently create a suspension of individual skin cells for use in the treatment of severe burns, chronic wounds, and other skin defects. Avita Medical focuses on improving patient outcomes and quality of life by providing personalized and regenerative treatments that enhance the natural healing process of the body. The company operates with a commitment to delivering advancements in healing and aesthetics through its cutting-edge products and therapies.


   Company Address: 28159 Avenue Stanford Valencia 91355 CA
   Company Phone Number: 367-9170   Stock Exchange / Ticker: NASDAQ RCEL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ANIK   -1.37%    
ESTA        5.17% 
IART   -1.01%    
MDXG        1.56% 
MMM   -3.32%    
SYK   -8.33%    
• View Complete Report
   



Product Service News

AVITA Medical Pioneers Advanced Burn Care with RECELL and Cohealyx, Marking a New Era in Patient Treatment an...

Published Wed, Oct 29 2025 4:52 PM UTC

In a significant step towards enhancing patient care for burn injuries, AVITA Medical has received positive endorsement from the Medical Services Advisory Committee (MSAC) in Australia for its groundbreaking RECELL system. This innovative technology offers promising treatment solutions by harnessing the body s own healing capabilities, effectively transforming the landscape ...

Clinical Study

Augmenting Wound Care AVITA Medicals RECELL and COHEALYX Transform Healing and Recovery,

Published Mon, Jun 9 2025 5:24 PM UTC

Presented by CSIMarket.com In a groundbreaking presentation at the BBA 2025, AVITA Medical showcased the largest real-world analysis of its RECELL system, highlighting its potential to revolutionize inpatient burn care. Combining technological innovation with economic impact offers encouraging results for healthcare providers and patients alike. This article delves into t...

Clinical Study

AVITA Medical Unveils Cohealyx A Breakthrough Collagen-Based Dermal Matrix Set to Transform Healing Landscapes and Ex...

Published Fri, Apr 4 2025 8:01 AM UTC

In a pivotal move that underscores its commitment to advancing medical technologies, AVITA Medical has announced the U.S. launch of Cohealyx, a revolutionary collagen-based dermal matrix specifically engineered to enhance tissue integration and foster revascularization. This innovative product signifies not just a stride in the realm of wound healing but also opens up new op...

Product Service News

AVITA Medicals FDA Clearance Paves the Way Amidst Financial Challenges An In-Depth Look

Published Thu, Dec 19 2024 10:05 PM UTC

In a significant turn of events for AVITA Medical (NASDAQ: AVTA), the company has recently announced the FDA’s 510(k) clearance for its innovative product, Cohealyx. This regulatory approval expands AVITA s addressable market, suggesting new growth opportunities that could bolster its standing in the competitive healthcare landscape. However, this achievement arrives on th...

Partnership

In a significant strategic move aimed at broadening its geographical footprint, AVITA Medical has announced...

Published Tue, Nov 12 2024 9:03 PM UTC

AVITA Medical Expands RECELL Product Platform to Australia and New Zealand through Exclusive Distribution Agreement In a significant strategic move aimed at broadening its geographical footprint, AVITA Medical has announced an exclusive distribution agreement poised to introduce its innovative RECELL product platform to the markets of Australia and New Zealand. This developm...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 4.55
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.19
Working Capital Ratio 0.44
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.48 $
Revenues (TTM) 2.46 $
Cash Flow (TTM) -
Cash 0.43 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 334,650
Net Income per Employee (TTM) -190,628
Receivable Turnover Ratio (TTM) 7.99
Inventory Turnover Ratio (TTM) 2.18
Asset Turnover Ratio (TTM) 0.99

Profitability Ratios Current
Gross Margin (MRQ) 81.87 %
Operating Margin (MRQ) -31.59 %
Net Margin (MRQ) -35.31 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Avita Medical Inc's Segments
Recell Go Preparation Kit    92.16 % of total Revenue
US    181.62 % of total Revenue
JP    3.81 % of total Revenue
United Kingdom    1.84 % of total Revenue
Recell System    166.67 % of total Revenue
Cohealyx    14.95 % of total Revenue
PermeaDerm    4.8 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.